Dendritic cell-based cancer immunotherapies. Sep 2009 - Arch. Immunol. Ther. Exp. (Warsz.); 57(3):1661-4917 [PMID:19479202] [Fujii S] [Takayama T] [Asakura M] [Aki K] [Fujimoto K] [Shimizu K]
Induction of peptide-specific immune response in patients with primary malignant melanoma of the esophagus after immunotherapy using dendritic cells pulsed with MAGE peptides. Mar 2007 - Jpn. J. Clin. Oncol.; 37(2):1465-3621 [PMID:17255158] [Ueda Y] [Shimizu K] [Itoh T] [Fuji N] [Naito K] [Shiozaki A] [Yamamoto Y] [Shimizu T] [Iwamoto A] [Tamai H] [Yamagishi H]
Intrahepatic cholangiocarcinoma with lymph node metastasis successfully treated by immunotherapy with CD3-activated T cells and dendritic cells after surgery: report of a case. May 2006 - Surg. Today; 36(6):0941-1291 [PMID:16715430] [Higuchi R] [Yamamoto M] [Hatori T] [Shimizu K] [Imai K] [Takasaki K]
Tumor-dendritic cell fusion as a basis for cancer immunotherapy. Jun 2005 - Otolaryngol Head Neck Surg; 132(5):0194-5998 [PMID:15886631] [Lee WT] [Shimizu K] [Kuriyama H] [Tanaka H] [Kjaergaard J] [Shu S]
